Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy.
Having noted symptomatic osteoporotic vertebral collapse in young adult survivors of childhood malignancy, bone mineral density (BMD) was examined at three sites by dual-energy X-ray absorptiometry in 64 patients treated in childhood for intracranial malignancy (group 1; n = 21) or acute leukaemia (group 2; n = 43). Patients in group 1 were selected for growth hormone deficiency (GHD) by auxological and biochemical criteria before the end of puberty (Tanner stage V). Seven patients (six men; mean (+/- SEM) age at study, 28.0 +/- 2.9 years; mean age at diagnosis, 8.7 +/- 1.5 years) in this group had been treated with human pituitary growth hormone (GH) for 1-12 years; and 14 patients (nine men; mean age at study, 26.8 +/- 1.0 years; mean age at diagnosis, 10.7 +/- 1.4 years) had not received GH. Bone densities in group 1 were normal in the GH-treated patients at the femoral neck (98.4 +/- 3.8% of control), lumbar spine (100.4 +/- 6.1% of control) and Ward's triangle (101.0 +/- 6.1% of control) but markedly reduced in the untreated group (femoral neck, 81.2 +/- 2.6% of control (p = 0.002); lumbar spine, 79.1 +/- 4.1% of control (p = 0.04); Ward's triangle, 80.1 +/- 3.6% of control (p = 0.01)). The majority of patients in group 2 had been treated for acute lymphoblastic leukaemia (ALL) and were in three subgroups.(ABSTRACT TRUNCATED AT 250 WORDS)
Nussey
S S
SS
Department of Medicine, St George's Hospital Medical School, London, UK.
Hyer
S L
SL
Brada
M
M
Leiper
A D
AD
Pazianas
M
M
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002113:Calcification, Physiologic / Q000187:drug effects*; D005260:Female; D013006:Growth Hormone / Q000172:deficiency* / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008297:Male; D009369:Neoplasms / Q000150:complications*; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology
D013006:Growth Hormone